Alectinib (Alecensa) as monotherapy for first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)

Home  /  National Uptake and Case Studies  /  Alectinib (Alecensa) as monotherapy for first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)
CountryAgencyYear work was carried outLinkDetails of use
AustriaGOeG2018-Dissemination to decision-makers.
AustriaHVB2018LINKNational adaptation. Made minor changes to information used. Added budget impact or cost effectiveness analysis.
CroatiaAAZ2018LINK National adaptation. Carried out translation. Added local information
DenmarkDanish Medicines Council2018LINKCited in report as background information.
ItalyASSR RER2018Dissemination through our website: alert of publication and link to document; summary and results reported on news page
ItalyUCSC2018National adaptation. Added local information.
HungaryNIPN2018Used to justify our findings in the Technology Appraisal Committee meeting
NorwayNOMA2018LINKNational adaptation. Added local information.
PortugalINFARMED2018National adaptation. Translated report. Added local information.
SlovakiaUNIBA2018National adaptation. Added local information.
SpainAEMPS2018LINKCited in report as background or additional information.
SpainOSTEBA2018LINK
PTJA03 assessment disseminated to oncologists and relevant decision makers (managers of the Pharmacy section of the Basque Health Service).
SpainAETSA2018LINK National adaptation. No changes to the information. Translated into Spanish.

A summary of this assessment in Spanish together with the full English report has been published on AETSA's website for dissemination. In addition, the report has been distributed to regional decision-makers and oncologists.
SwedenTLV2018LINKNational adaptation. Added local information.
UK (England)NICE2018LINKRead the assessment for background information. Used the assessment to inform the evaluation or consideration of a company submission of evidence.
UK (Scotland)SMC2018LINKUsed the assessment to inform the evaluation or consideration of a company submission of evidence. Updated evidence.
FinlandHILA2018Read the report for background information. Were unable to fully utilize the report due to a different comparator. HILA also have to present our assessments in Finnish and in a specific structure.
AustriaLBI-HTA2018LINK1:1 in LBI-HTA Horison Scanning in Oncology-programme.
IrelandNCPE2018-2019-Read the assessment for background information.
PolandAOTMiT2018-2019-National adaptation. Added local information.
Czech RepublicSUKL2019-Used as background information.